Quantum Genesis AI Corp. (OTC: QGAI) has issued a statement regarding the Caveat Emptor designation applied to its securities by OTC Markets Group, Inc. on February 12, 2026. The company, which focuses on artificial intelligence, computational modeling, and scientific innovation, has been attempting to communicate with OTC Markets to understand the basis for the designation, which OTC Markets has indicated relates to a "public interest concern."
Since the designation was applied, the company has sought additional clarification and intends to continue cooperating with OTC Markets. OTC Markets recently informed Quantum Genesis AI that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. The company plans to engage with OTC Markets at the earliest available opportunity to initiate that review process.
"We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation," said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. "Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process."
The company remains committed to maintaining transparency with its shareholders and the broader investment community. Quantum Genesis AI intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available.
For more information and updates, please visit www.qgaicorp.com and the company's profile at www.otcmarkets.com/stock/QGAI.
